Today's Technology For Tomorrow's Kidney Care

In transition from Kidney health supplement to progress as a live biotherapeutic drug product development under CBER/USFDA. Submission of the Investigational New Drug(IND) application is in the process.
Intestinal Dialysis™ (a.k.a Enteric Dialysis®) – Modulating the Gut Microbiome with Probiotics and Prebiotics (Gut-Kidney Connection)

2020 Business of the Year
Delaware County Chamber of Commerce

Bio - Biotechnology Innovation Organization
2005 - Innovation Corridor Abstract Winner, Boston, MA
2018 - Invited Company for Presentation, Boston, MA

2014 - Winner of “Buzz of Bio Awards”
The First dietary supplement Company to win this award. International Bio conference, San Diego, CA

2019 - Dun & Bradstreet Award
In recognition of unwavering commitment to business growth
From www.theisn.org
SYMPOSIUM AT THE INTERNATIONAL SOCIETY OF ARTIFICIAL INTERNAL ORGANS IN EDINBURGH, SCOTLAND. Aug 04, 1999
850 million Adult
Worldwide 850 million adult are estimated to have Chronic Kidney Disease (CKD)
Risk Factors Include
Rick Factors for CKD includes diabetes, high blood pressure, heart disease, Obesity and Family history of Kidney problems
An estimated 1 in 10
An estimated 1 in 10 people worldwide have Chronic Kidney Disease (CKD)

Utenim ad minim eniami quis nostrud exer.

Supported by Visionary & Distinguished Nephrologists and Scientists
SYMPOSIUM AT THE INTERNATIONAL SOCIETY OF ARTIFICIAL INTERNAL ORGANS IN EDINBURGH, SCOTLAND. Aug 04, 1999

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.
